Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.50)
# 913
Out of 5,090 analysts
13
Total ratings
72.73%
Success rate
15.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $33.45 | +91.33% | 2 | Dec 1, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Hold | n/a | $9.61 | - | 2 | Nov 11, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $40.29 | +14.17% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $18.55 | +29.38% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $6.39 | +322.54% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $4.18 | +833.01% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $16.43 | +82.59% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $11.04 | +108.33% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $26.42 | +74.11% | 1 | Sep 19, 2024 |
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $33.45
Upside: +91.33%
Intellia Therapeutics
Nov 11, 2025
Downgrades: Hold
Price Target: n/a
Current: $9.61
Upside: -
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $40.29
Upside: +14.17%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $18.55
Upside: +29.38%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $6.39
Upside: +322.54%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $4.18
Upside: +833.01%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $16.43
Upside: +82.59%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $11.04
Upside: +108.33%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $26.42
Upside: +74.11%